摘要
目的观察舒利迭50μg/500μg(沙美特罗/氟替卡松吸入剂)治疗稳定期重度慢性阻塞性肺疾病(COPD)的临床疗效。方法50例重度COPD患者随机分为试验组和对照组,各25例,均给予舒利迭早晚各1吸,2次/d,但实验组每1吸50μg/500μg,对照组每1吸50μg/250μg,疗程均为3个月。常规处理有劝导戒烟、注射流感疫苗。基本治疗为口服氨茶碱片0.1g/次,3次/d,氨溴索片30mg/次,3次/d。治疗前后测定临床症状评分及第1秒钟用力呼气量(FEV1)、FEV1/用力肺活量(FVC)、FEV1占预计值百分比。结果44例患者最终完成试验,试验组23例,对照组21例,两组治疗前、后临床症状评分明显改善(P<0.05),两组间没有明显差异(P>0.05)。实验组与对照组治疗前后肺功能FEV1、FEV1/FVC、FEV1占预计值百分比均明显改善(P<0.05);治疗后两组间比较,差异有显著性(P<0.05)。结论沙美特罗/氟替卡松吸入剂治疗COPD疗效肯定,舒利迭50μg/500μg治疗稳定期重度COPD效果优于舒利迭50μg/250μg。
[ Objective ] To explore the clinical effects of Seretide （Salmeteral/Fluticasone）50 μg/500 μg in the control of severe COPD patients in stable period. [ Method ]50 patients with severe COPD were divided randomly into two groups, each group were 25 patients, the test group was given SM/FP （50/500μg）, twice a day, and the control group was give SM/FP （50/250 μg）, twice a day, for 3 months. Other treatment was the same just like quiting smoking and influenza vaccination. Basic treatment was taking aminophylline tablets 0.1 g each time, 3 times one day, ambroxol tablets, 30mg each time, 3 times one day. The changes of clinical symptom, pulmonary function （FVC, FEV1 and FEV1%） before and after inhale were observed. [Result] 44 patients completed the final test, the test group 23 examples, the control group 21 examples. The clinical symptom of two groups were improved significantly after treatment with Seretide, but with no statistically significant difference between the two groups. The values of pulmonary function （FVC, FEV1 and FEV1%） were higher than those before treatment ,and there was statistically significant difference between the two groups. [ Conclusion ] Seretide has clinical effect in COPD. The use of greater dose（50/500 μg） of Seretide is a better choice to severe COPD patients in stable period.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2009年第19期3023-3025,共3页
China Journal of Modern Medicine
